The European Commission approved Amgen’s cardiovascular drug Repatha to reduce risk in adults with established conditions like myocardial infarction, stroke or peripheral arterial disease. The label update follows data from a Repatha outcomes study that showed a 20 percent reduction in major adverse cardiovascular events when it was combined with statin therapy, including a 27…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
